The data support the ADA’s recommendations regarding the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly Semaglutide and Tirzepatide, in managing type 2 diabetes mellitus (T2DM) in individuals with pre-existing cardiovascular disease or those at high risk for cardiovascular disease (CVD). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.